SGMO Announces CFO Transition with Interim Financial Oversight

Rhea-AI Filing Summary

Sangamo Therapeutics reported that its Chief Financial Officer, Prathyusha Duraibabu, notified the company on September 9, 2025 that she will resign effective October 1, 2025 to join a privately-held artificial intelligence company. The filing states her departure is not due to any disagreement over the company’s operations, financial statements, internal controls, auditors, policies, or practices. For business continuity, Ms. Duraibabu will move to part-time employment on the Transition Date and will continue to serve as the company’s principal financial officer and principal accounting officer on an interim basis until a successor is appointed. The company acknowledged her contributions, including work on strategic collaborations and investment allocations as Sangamo focuses on becoming a neurology-focused genomic medicines company.

Positive

• Planned transition with continuity: CFO will remain part-time and serve as interim principal financial officer to support a smooth handover
• No disagreement disclosed: Resignation explicitly stated as not related to operations, financial statements, internal controls, auditors, policies, or practices
• Recognition of contributions: Company highlighted CFO's role in strategic collaborations and investment allocations aligned with its neurology focus

Negative

• Senior leadership change: Resignation of the CFO creates succession uncertainty until a permanent replacement is appointed
• Potential near-term execution risk: Part-time interim coverage may limit full-time strategic oversight during the transition period

Insights

Corporate Governance Expert

TL;DR: CFO resignation with an interim transition reduces immediate disruption risk but creates near-term succession uncertainty.

The filing discloses a voluntary resignation effective October 1, 2025 with explicit language that the departure is not related to disagreements about controls or financial reporting, which mitigates regulatory and disclosure risk. Retaining Ms. Duraibabu part-time and as interim principal financial and accounting officer supports continuity in financial leadership during the search for a successor. Material issues for investors include the timeline and profile of the successor, and whether the interim arrangement impacts audit or SEC reporting processes. From a governance perspective, the board's succession planning and communication will be important to monitor.

Securities Analyst

TL;DR: Leadership change is noteworthy but immediate operational impact appears limited due to interim coverage.

The company frames the change as voluntary and unrelated to operational or accounting disputes, which typically reduces adverse market reaction. The interim arrangement preserves institutional knowledge and ongoing work on strategic collaborations cited in the filing. Key investor concerns that remain unanswered in this disclosure are the expected duration of the interim period, characteristics of the eventual successor, and any near-term effects on financial planning or capital allocation. Absent additional material facts, this is a notable but not necessarily market-moving disclosure.

0001001233false00010012332025-09-092025-09-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2025

 SANGAMO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

  

Delaware

000-30171

68-0359556

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer ID Number)

501 Canal Blvd., Richmond, California 94804

(Address of principal executive offices) (Zip Code)

(510) 970-6000

(Registrant’s telephone number, including area code) 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report) 

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value per share

SGMO

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 9, 2025, Prathyusha Duraibabu, notified Sangamo Therapeutics, Inc. (the “Company”) of her decision to resign from her position as Chief Financial Officer of the Company, effective October 1, 2025 (the “Transition Date”), in order to assume a senior leadership role with a privately-held artificial intelligence company. Ms. Duraibabu’s resignation is not due to any disagreement relating to the Company’s operations, financial statements, internal controls, auditors, policies or practices. Ms. Duraibabu currently serves as principal financial officer and principal accounting officer of the Company. For purposes of business continuity, effective as of the Transition Date, Ms. Duraibabu will transition to part-time employment with the Company, following which she will continue to serve as the Company’s principal financial officer on an interim basis pending the appointment of a successor. The Company thanks Ms. Duraibabu for her significant contributions as Chief Financial Officer, including her key role in our strategic collaborations and investment allocations that have positioned the Company for its future as a neurology-focused genomic medicines company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

SANGAMO THERAPEUTICS, INC.

Dated: September 11, 2025

By:

/s/ SCOTT B. WILLOUGHBY

Name:

Scott B. Willoughby

Title:

Chief Legal Officer and Corporate Secretary

FAQ

What did Sangamo (SGMO) disclose about its CFO on the 8-K?

The company disclosed that CFO Prathyusha Duraibabu notified Sangamo on September 9, 2025 she will resign effective October 1, 2025 and will transition to part-time while serving as interim principal financial officer.

Is the CFO resignation related to any disagreement over financial controls or policies?

No. The filing states the resignation is not due to any disagreement relating to the company’s operations, financial statements, internal controls, auditors, policies, or practices.

Will the CFO continue working for Sangamo after the resignation date?

Yes. Effective as of the Transition Date, she will transition to part-time employment and will continue to serve as the company's principal financial officer on an interim basis until a successor is appointed.

Did Sangamo describe the CFO’s contributions?

Yes. The company thanked Ms. Duraibabu for significant contributions, including a key role in strategic collaborations and investment allocations supporting the company’s shift toward neurology-focused genomic medicines.

Does the filing state who will replace the CFO?

No. The filing indicates a successor will be appointed but does not provide a timeline or identify the successor.